Insilico Medicine Partners with Takeda on AI-Driven Drug Discovery; Shenyang Angina Pharma Penalized for Invoice Fraud
CSPC
Innovative Drug Research and Development, Manufacturer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Amino Observation - Original Production by the Innovative Drug Group
Author | Huang Kai
On July 2, the National Healthcare Security Administration’s official WeChat account published an article directly addressing a case involving fraudulent invoicing.
Shenyang Origin Pharmaceutical Co., Ltd. was subjected to administrative penalties by the First Inspection Bureau of the Shenyang Municipal Tax Service, State Taxation Administration (Penalty Decision No. 37 [2026] of the First Inspection Bureau of Shenyang Tax) for obtaining falsely issued value-added tax (VAT) invoices. Between January 2017 and December 2024, Shenyang Origin Pharmaceutical Co., Ltd. obtained 2,083 sets of falsely issued VAT invoices from 40 enterprises, including Shenyang XX Pharmaceutical Technology Co., Ltd. and Shenyang XX Management Consulting Co., Ltd., in the absence of genuine transactions. These invoices were used to fraudulently deduct input VAT and inflate operating costs and expenses, with the total amount including tax reaching RMB 189 million. In accordance with relevant regulations, the First Inspection Bureau of the Shenyang Municipal Tax Service, State Taxation Administration, imposed an administrative fine of RMB 35.16 million.
Insilico Medicine Continues to Forge Partnerships.
On July 2, Insilico Medicine announced a global strategic collaboration with Takeda Pharmaceutical Company. Leveraging its proprietary end-to-end Pharma.AI platform, the two companies will jointly advance the development of candidate drugs in multiple therapeutic areas selected by Takeda. Insilico Medicine will receive approximately $60 million in upfront and near-term milestone payments. Additionally, it is eligible for milestones based on preclinical, clinical, commercialization, and sales progress, bringing the total potential deal value to approximately $600 million, as well as tiered royalties on future sales post-commercialization. Takeda will obtain exclusive global rights to develop, manufacture, and commercialize the novel therapies identified through this collaboration.
What other hot topics in the domestic and international pharmaceutical markets are worth paying attention to in the past day? Let Amin Jun take you to explore.
/ 01 /
Market Express
1) Insilico Medicine and Takeda Pharmaceutical Reach AI-Driven New Drug Development Collaboration
On July 2, Insilico Medicine announced a global strategic collaboration with Takeda Pharmaceutical Company. Leveraging its proprietary, integrated end-to-end Pharma.AI platform, the two companies will jointly advance the development of candidate drugs in multiple therapeutic areas selected by Takeda. Insilico Medicine will receive approximately $60 million in upfront and near-term milestone payments. Additionally, it is eligible for further milestones based on preclinical, clinical, commercialization, and sales progress, bringing the total potential deal value to approximately $600 million, plus tiered royalties on future sales after product commercialization. Takeda will obtain exclusive global rights to develop, manufacture, and commercialize the novel therapies identified through this collaboration.
2) CSPC and AstraZeneca Reach New Partnership
On July 2, CSPC announced that it had entered into a collaboration, option, and license agreement with AstraZeneca to establish a strategic R&D partnership and leverage CSPC’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to develop novel small nucleic acid candidate drugs.
3) Abbisko Therapeutics and AstraZeneca Enter into Strategic Collaboration
On July 2, Abbisko Therapeutics announced that it had entered into a strategic collaboration agreement with AstraZeneca to jointly advance clinical studies evaluating the oral small-molecule PD-L1 inhibitor ABSK043 (lumipodlin) in combination with AstraZeneca’s third-generation EGFR-TKI Tagrisso (osimertinib) for the treatment of non-small cell lung cancer.
4) The National Healthcare Security Administration’s official WeChat account published an article directly addressing a case involving fraudulent invoicing.
On July 2, the National Healthcare Security Administration issued a statement announcing that Shenyang Aojina Pharmaceutical Co., Ltd. had been subjected to an administrative penalty by the First Inspection Bureau of the Shenyang Municipal Tax Service, State Taxation Administration (Penalty Decision No. 37 [2026] of Shen Shui Ji Yi), for obtaining falsely issued value-added tax (VAT) invoices. Between January 2017 and December 2024, Shenyang Aojina Pharmaceutical Co., Ltd. obtained 2,083 sets of falsely issued VAT invoices from 40 enterprises, including Shenyang XX Pharmaceutical Technology Co., Ltd. and Shenyang XX Management Consulting Co., Ltd., in the absence of genuine transactions. These invoices were used to fraudulently claim input tax credits and inflate operating costs and expenses, with the total amount including tax reaching RMB 189 million. In accordance with relevant regulations, the First Inspection Bureau of the Shenyang Municipal Tax Service, State Taxation Administration, imposed an administrative fine of RMB 35.16 million.
/ 02 /
Capital Information
1) Ruijian Pharma Announces Completion of RMB 260 Million in Series C+ Financing
On July 2, Ruijian Pharma announced the completion of its C+ round financing amounting to RMB 260 million. As an innovative pharmaceutical company, Ruijian Pharma focuses on Parkinson’s disease, retinal degenerative diseases, and metabolic function decline.
/ 03 /
Pharmaceutical News
1) Baicheng Pharmaceutical's BIOS0629-109 Tablets Receive Clinical Trial Approval
On July 2, Baicheng Medicine announced that the innovative drug XPO1 inhibitor BIOS0629-109 tablets, co-developed with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd., had received clinical trial approval from the National Medical Products Administration (NMPA), permitting clinical trials of the monotherapy in patients with advanced malignant tumors.
2) Shanweite Bio’s YB1-X7 Injection (for Intravenous Infusion) Granted Clinical Trial Approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Shanweite Biologics’ YB1-X7 injection (for intravenous infusion) received clinical trial approval, with plans to conduct studies on the treatment of advanced solid tumors.
3) Beiteruima Bio’s BPR-30160639 Injection Receives Clinical Trial Approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Beiteruima Bio’s BPR-30160639 injection received clinical trial approval for the proposed treatment of chronic hepatitis B.
4) If Yi Shengwu’s Recombinant Botulinum Toxin Type A for Injection obtains clinical trial approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Ruoyi Biotechnology’s injectable recombinant botulinum toxin type A received clinical trial approval, with plans to conduct studies on the treatment of rosacea characterized by persistent facial erythema and paroxysmal flushing in adults.
/ 04 /
Global Pharma News
1) Roche’s KRAS G12C Inhibitor Succeeds in Head-to-Head Clinical Trial
On July 2, Roche announced positive results from the Phase III Krascendo 1 study. The study evaluated the efficacy of the investigational next-generation KRAS G12C inhibitor divarasib versus the approved first-generation KRAS G12C inhibitors sotorasib or adagrasib in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study met its primary and key secondary endpoints, with divarasib demonstrating clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS).